A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-03-10 , DOI: 10.1111/dom.14023
David R Webb _{1,

2} , Zin Zin Htike ₁ , Daniel J Swarbrick ₃ , Emer M Brady ₃ , Laura J Gray ₄ , John Biglands ₅ , Gaurav S Gulsin ₃ , Joseph Henson _{1,

2} , Kamlesh Khunti _{1,

2} , Gerry P McCann _{2,

3} , Helen L Waller _{1,

2} , M'Balu A Webb _{1,

2} , Jack A Sargeant _{1,

2} , Thomas Yates _{1,

2} , Francesco Zaccardi ₁ , Melanie J Davies _{1,

2}

Affiliation

To compare the effects of a glucagon‐like peptide‐1 receptor agonist and a dipeptidyl peptidase‐4 inhibitor on magnetic resonance imaging‐derived measures of cardiovascular function.

中文翻译：